中国结直肠癌诊疗规范(2017版)主要更新概要

2018-01-10 中华胃肠外科杂志.2018.21(1):90-91.

2017 版《规范》既参考了国际指南的内容,更结合了中国的具体国情和临床实践,同时囊括了近些年来我国结直肠癌领域的重要进展和许多自己的循证学临床数据。相信,2017版《规范》将会进一步推动我国结直肠癌的整体诊疗水平袁改善患者的生存和预后,造福千万结直肠癌患者及其家庭。

中文标题:

中国结直肠癌诊疗规范(2017版)主要更新概要

发布机构:

发布日期:

2018-01-10

简要介绍:

2017 版《规范》既参考了国际指南的内容,更结合了中国的具体国情和临床实践,同时囊括了近些年来我国结直肠癌领域的重要进展和许多自己的循证学临床数据。相信,2017版《规范》将会进一步推动我国结直肠癌的整体诊疗水平袁改善患者的生存和预后,造福千万结直肠癌患者及其家庭。

 

拓展指南:结直肠癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=中国结直肠癌诊疗规范(2017版)主要更新概要)] GetToolGuiderByIdResponse(projectId=1, id=1a16a1c0015a4555, title=中国结直肠癌诊疗规范(2017版)主要更新概要, enTitle=, guiderFrom=中华胃肠外科杂志.2018.21(1):90-91., authorId=null, author=, summary=2017 版《规范》既参考了国际指南的内容,更结合了中国的具体国情和临床实践,同时囊括了近些年来我国结直肠癌领域的重要进展和许多自己的循证学临床数据。相信,2017版《规范》将会进一步推动我国结直肠癌的整体诊疗水平袁改善患者的生存和预后,造福千万结直肠癌患者及其家庭。 , cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Jan 10 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2017 版《规范》既参考了国际指南的内容,更结合了中国的具体国情和临床实践,同时囊括了近些年来我国结直肠癌领域的重要进展和许多自己的循证学临床数据。相信,2017版《规范》将会进一步推动我国结直肠癌的整体诊疗水平袁改善患者的生存和预后,造福千万结直肠癌患者及其家庭。 </P> <P> </P>拓展指南:<strong>与<font color=red>结直肠癌</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=4e2e11c0015a080b" title="2017 ASER/POQI联合共识声明:加速择期结直肠癌手术康复术后胃肠功能紊乱" target=_blank>2017 ASER/POQI联合共识声明:加速择期结直肠癌手术康复术后胃肠功能紊乱</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=631c51c00153899c" title="2017 共识建议:囊性纤维化结直肠癌筛查" target=_blank>2017 共识建议:囊性纤维化结直肠癌筛查</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=16dde1c001536888" title="2017 加拿大共识声明:原发肿瘤位置在转移性结直肠癌的治疗的预期作用" target=_blank>2017 加拿大共识声明:原发肿瘤位置在转移性结直肠癌的治疗的预期作用</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=d1c921c0015339ab" title="中国结直肠癌诊疗规范(2017版)" target=_blank>中国结直肠癌诊疗规范(2017版)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=5c63f1c00152a62d" title="结直肠癌腹膜转移诊治中国专家意见(2017)" target=_blank>结直肠癌腹膜转移诊治中国专家意见(2017)</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%BB%93%E7%9B%B4%E8%82%A0%E7%99%8C" target=_blank>有关结直肠癌更多指南</a></ul>, tagList=[TagDto(tagId=539, tagName=结直肠癌), TagDto(tagId=540, tagName=诊疗规范)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6412, appHits=848, showAppHits=7, pcHits=4512, showPcHits=1557, likes=138, shares=9, comments=5, approvalStatus=1, publishedTime=Tue Jan 16 22:16:16 CST 2018, publishedTimeString=2018-01-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Jan 16 22:16:16 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 02:21:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中国结直肠癌诊疗规范(2017版)主要更新概要)])
中国结直肠癌诊疗规范(2017版)主要更新概要
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=366947, encodeId=edd936694e26, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef65108426, createdName=2460c931m, createdTime=Wed May 29 03:45:55 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280678, encodeId=8bab2806e8f7, content=全身各种肿瘤诊疗规范一直在前进, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Jan 21 12:34:46 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279333, encodeId=7d212e9333bc, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 17 08:11:46 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279321, encodeId=add92e93211b, content=了解了解.继续关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 17 07:55:26 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279230, encodeId=cebe2e9230ea, content=谢谢.学习受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jan 16 23:35:35 CST 2018, time=2018-01-16, status=1, ipAttribution=)]
    2019-05-29 2460c931m

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=366947, encodeId=edd936694e26, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef65108426, createdName=2460c931m, createdTime=Wed May 29 03:45:55 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280678, encodeId=8bab2806e8f7, content=全身各种肿瘤诊疗规范一直在前进, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Jan 21 12:34:46 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279333, encodeId=7d212e9333bc, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 17 08:11:46 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279321, encodeId=add92e93211b, content=了解了解.继续关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 17 07:55:26 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279230, encodeId=cebe2e9230ea, content=谢谢.学习受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jan 16 23:35:35 CST 2018, time=2018-01-16, status=1, ipAttribution=)]
    2018-01-21 邓启付

    全身各种肿瘤诊疗规范一直在前进

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=366947, encodeId=edd936694e26, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef65108426, createdName=2460c931m, createdTime=Wed May 29 03:45:55 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280678, encodeId=8bab2806e8f7, content=全身各种肿瘤诊疗规范一直在前进, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Jan 21 12:34:46 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279333, encodeId=7d212e9333bc, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 17 08:11:46 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279321, encodeId=add92e93211b, content=了解了解.继续关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 17 07:55:26 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279230, encodeId=cebe2e9230ea, content=谢谢.学习受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jan 16 23:35:35 CST 2018, time=2018-01-16, status=1, ipAttribution=)]
    2018-01-17 Y—xianghai

    学习了新知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=366947, encodeId=edd936694e26, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef65108426, createdName=2460c931m, createdTime=Wed May 29 03:45:55 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280678, encodeId=8bab2806e8f7, content=全身各种肿瘤诊疗规范一直在前进, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Jan 21 12:34:46 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279333, encodeId=7d212e9333bc, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 17 08:11:46 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279321, encodeId=add92e93211b, content=了解了解.继续关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 17 07:55:26 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279230, encodeId=cebe2e9230ea, content=谢谢.学习受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jan 16 23:35:35 CST 2018, time=2018-01-16, status=1, ipAttribution=)]
    2018-01-17 1dd8c52fm63(暂无匿称)

    了解了解.继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=366947, encodeId=edd936694e26, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef65108426, createdName=2460c931m, createdTime=Wed May 29 03:45:55 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280678, encodeId=8bab2806e8f7, content=全身各种肿瘤诊疗规范一直在前进, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzcjoLTEEgkSSQ8pVIiaf4a4INaoMLBV16QEk3dvvBRpicwIwmDGv0jePErJ4aE9ibVBDPtkialQLT9Bs/0, createdBy=04811949400, createdName=邓启付, createdTime=Sun Jan 21 12:34:46 CST 2018, time=2018-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279333, encodeId=7d212e9333bc, content=学习了新知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jan 17 08:11:46 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279321, encodeId=add92e93211b, content=了解了解.继续关注, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Jan 17 07:55:26 CST 2018, time=2018-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279230, encodeId=cebe2e9230ea, content=谢谢.学习受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Jan 16 23:35:35 CST 2018, time=2018-01-16, status=1, ipAttribution=)]
    2018-01-16 清风拂面

    谢谢.学习受益匪浅

    0